Isofol Medical AB (publ)

SSE:ISOFOL.ST

0.62 (SEK) • At close February 20, 2024
Bedrijfsnaam Isofol Medical AB (publ)
Symbool ISOFOL.ST
Munteenheid SEK
Prijs 0.616
Beurswaarde 99,493,240
Dividendpercentage 0%
52-weken bereik 0.45 - 1.24
Industrie Biotechnology
Sector Healthcare
CEO Dr. Roger Tell M.D., Ph.D.
Website https://isofolmedical.com

An error occurred while fetching data.

Over Isofol Medical AB (publ)

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital.

Vergelijkbare Aandelen

C-Rad AB (publ) logo

C-Rad AB (publ)

CRAD-B.ST

46.55 SEK

Cantargia AB (publ) logo

Cantargia AB (publ)

CANTA.ST

3.32 SEK

Diamyd Medical AB (publ) logo

Diamyd Medical AB (publ)

DMYD-B.ST

13.3 SEK

Senzime AB (publ) logo

Senzime AB (publ)

SEZI.ST

7.25 SEK

Xspray Pharma AB (publ) logo

Xspray Pharma AB (publ)

XSPRAY.ST

44 SEK

ADDvise Group AB (publ) logo

ADDvise Group AB (publ)

ADDV-A.ST

11.6 SEK

Xbrane Biopharma AB (publ) logo

Xbrane Biopharma AB (publ)

XBRANE.ST

2.085 SEK

Mentice AB (publ) logo

Mentice AB (publ)

MNTC.ST

34.4 SEK

Doxa AB (publ) logo

Doxa AB (publ)

DOXA.ST

3.2 SEK

IRLAB Therapeutics AB (publ) logo

IRLAB Therapeutics AB (publ)

IRLAB-A.ST

14.45 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)